← Leaderboards
Parinda A. Mehta
Cincinnati Childrens Hosp Med Ctr
$3,328,864
Attributed
$3,328,864
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $737.1K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$2,336,981 · 2
NIH$991,883 · 1
By mechanism
R01$3,328,864 · 3
Top collaborators
No co-investigators on record.
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Paul R Andreassen$3,175,027
- Vidya Chidambaran$7,050,743
- Rebecca Marsh$1,164,079
Others in their field
Top investigators on “Failure”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Constance Ann Benson · University Of California, San Diego$187,132,366
- David M Nathan · Massachusetts Institute Of Technology$129,771,015
- John M Lachin · George Washington University$122,721,121
- Judith S Hochman · New York University School Of Medicine$119,832,568
- Wafaa M. El-Sadr · Columbia University Health Sciences$95,753,873
Research focus
FailureFallsAcute Graft Versus Host DiseaseAllogenicBody Surface AreaAlemtuzumabAge GroupCd4 Positive T LymphocytesCdw52 GeneCell CountChildhoodChimerismClinical TrialsConditioningBone Marrow TransplantationCurative TreatmentsDashboardDoseDrug KineticsElectronicsEnrollmentEnsureEvaluationFeasibility Studies
Grant awards (10)
Precision Alemtuzumab Therapy in Allogeneic HCT$361,487
R01 · FY2025 · HD · contact PI
Precision Alemtuzumab Therapy in Allogeneic HCT$329,539
R01 · FY2024 · HD · contact PI
IND: 113343 Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia$436,248
R01 · FY2023 · FD · contact PI
Precision Alemtuzumab Therapy in Allogeneic HCT$300,857
R01 · FY2023 · HD · contact PI
IND: 113343 Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia$433,807
R01 · FY2022 · FD · contact PI
IND: 113343 Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia$431,437
R01 · FY2021 · FD · contact PI
IND: 113343 Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia$435,489
R01 · FY2019 · FD · contact PI
Phase 1 Study of Quercetin for the Treatment of Fanconi Anemia$200,000
R01 · FY2015 · FD · contact PI
Phase 1 Study of Quercetin for the Treatment of Fanconi Anemia$200,000
R01 · FY2014 · FD · contact PI
Phase 1 Study of Quercetin for the Treatment of Fanconi Anemia$200,000
R01 · FY2013 · FD · contact PI